Skip to Main content Skip to Navigation
Theses

Bénéfice thérapeutique d'un traitement par l'étifoxine (stresam™) dans les neuropathies accompagnées de comorbidités anxiodépressives : étude préclinique chez la souris

Abstract : Neuropathic pain is associated with significant co-morbidity, including anxiety and depression, which impact considerably on the overall patient experience. Several lines of evidence suggest that anxiolytics may be of interest to alleviate pain symptoms and the associated negative emotions in chronic pain states. Among them, the non-benzodiazepine anxiolytic etifoxine (EFX: stresam™) has an interesting pharmacological profile. In patients, it has a weak sedative action, with limited functional tolerance and dependence, and without cognitive declines. In this study, we aim at analyzing the preclinical therapeutic potential of etifoxine on the anxiodepressive consequences of neuropathic pain.
Complete list of metadata

https://tel.archives-ouvertes.fr/tel-01546013
Contributor : Abes Star :  Contact
Submitted on : Friday, June 23, 2017 - 12:15:25 PM
Last modification on : Wednesday, March 18, 2020 - 9:48:53 AM
Long-term archiving on: : Wednesday, January 10, 2018 - 9:51:02 PM

File

KAMOUN_Nisrine_2016_ED414.pdf
Version validated by the jury (STAR)

Identifiers

  • HAL Id : tel-01546013, version 1

Collections

Citation

Nisrine Kamoun. Bénéfice thérapeutique d'un traitement par l'étifoxine (stresam™) dans les neuropathies accompagnées de comorbidités anxiodépressives : étude préclinique chez la souris. Neurosciences [q-bio.NC]. Université de Strasbourg, 2016. Français. ⟨NNT : 2016STRAJ102⟩. ⟨tel-01546013⟩

Share

Metrics

Record views

977

Files downloads

90